Clinical Trial Update: Immunotherapy as Second-line in Patient With Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing immunotherapy as second-line treatment in small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage | Phase 2 | Status: COMPLETED